




The International Lung GVHD Consensus Conference 2026



23-25 SEPTEMBER 2026

CAMPUS BIOTECH, GENEVA, SWITZERLAND



Hôpitaux
Universitaires
Genève



UNIVERSITÉ
DE GENÈVE

FACULTÉ DE MÉDECINE

Dear Colleagues,

Over forty years ago, D. Ralph, E.D. Thomas and colleagues¹ reported a clinical syndrome of new onset severe airflow obstruction in association with chronic graft-versus-host disease in four young patients who had received marrow transplants for leukemia in Seattle, Washington. Lung biopsies revealed obliterative bronchiolitis, the fibrotic occlusion of small airways. Patients experienced debilitating breathlessness; treatment with corticosteroids did not provide objective benefit. Today, even in the era of improved prophylaxis and FDA-approved treatments for chronic GVHD, this original description of bronchiolitis obliterans syndrome - BOS - remains eerily cogent: we still do not have a cure for this highly morbid lung complication.

The impetus for a conference dedicated to lung GVHD arose out of a collective recognition that BOS is often diagnosed too late in its course for effective intervention. Since the landmark 2005 and 2014 NIH Chronic GVHD Consensus Conferences, our understanding of BOS and other potential forms of lung GVHD has grown, necessitating an updated clinical definition that would encourage early detection and treatment. Our ongoing discussions towards this update highlight how much we still need to learn about underlying disease processes and how to restore lung function.

To that end, we have convened critical mass of experts across the disciplines of pulmonary medicine, transplant hematology, immunology, infectious diseases, radiology, and statistical science, to review the current knowledge base and identify new avenues for investigation. Our goals in Geneva are i) to synthesize our understanding of lung GVHD disease pathogenesis, ii) update the definition of lung GVHD, and iii) establish an ideal clinical trial design for lung GVHD. Central to this conference is the critical work of the Lung GVHD Consensus Project Task Force: to propose an evidence-based revision of the NIH diagnostic criteria for lung GVHD that applies across the lifespan. We hope that this will promote rigorous clinical investigation, and more importantly, benefit HCT recipients around the world.

With the expanding global reach of allogeneic hematopoietic cell transplantation, understanding lung GVHD is more relevant than ever. We look forward to sharing three days of learning, insight, and fellowship that will extend beyond Geneva.

The Scientific Steering Committee

Anne Bergeron (Switzerland)

Daniel Wolff (Germany)

Joe Hsu (USA)

Sophie Paczesny (USA)

Corey Cutler (USA)

Steven Pavletic (USA/Croatia)

Guang-Shing Cheng (USA)

¹Ralph D et al. Am Rev Resp Dis 1984;129:641-644



GOAL: Synthesize preclinical understanding of the pathogenesis of BOS in the context of allogeneic hematopoietic cell transplant, identify translatable targets and key priorities for preclinical investigation

Co-Chairs: [Joe Hsu](#) and [Sophie Paczesny](#)

08:15 WELCOME PARTICIPANTS

08:30 Opening Remarks

[Prof Antoine Geissbuhler](#), *Dean of the University of Geneva*

08:35 Building on the ATS research statement and our understanding of the natural history of BOS

[Guang-Shing Cheng](#), *Fred Hutchinson Cancer Center*

08:50 Session 1: Knowledge Review

08:50 Specificities of airways disease after allogeneic HCT [Anne Bergeron](#), *University of Geneva*

09:05 Heterogeneity of airway pathology in clinical BOS: insights from microCT investigations in HCT, LT, and PIBO [Stijn Verleden](#), *UZA, University Hospital Antwerp*

09:25 Airway epithelial / endothelial injury [Jamie Todd](#), *Duke University*

09:45 Immunology of rejection and tolerance in lung allografts [Stephen Juvet](#), *University of Toronto*

10:05 The role of macrophages, cellular immunity, and alloimmune pathways in chronic GVHD [Julie Boiko](#), *Fred Hutchinson Cancer Center*

10:25 Discussion

10:35 Coffee Break

10:45 Session 2: Knowledge Review

10:45 Role of infection and microbiome in post-HCT lung injury [Matthew Zinter](#), *Univ of California San Francisco*

11:05 Dysbiosis and metabolomics in lung GVHD [David Michonneau](#), *University of Paris*

11:25 Viral infections and transplant alloimmunity [Louise Bondeelle](#), *University of Geneva*

11:45 Lessons from bronchiectasies: phentotypes, endotypes, and treatable traits [Alan Barker](#), *Oregon Health Sciences University*

12:05 DISCUSSION

12:15 LUNCH

13:15 The Patient Perspective [Andreas Mall](#), *Germany*

13:20 Session 3: Pro/Con Debate: Idiopathic pneumonia syndrome is a risk factor for lung GVHD

[Ken Cooke](#), *Johns Hopkins University* and [Ajay Sheshadri](#), *MD Anderson Cancer Center*

13:50 Discussion

14:00 Session 4: Pathways of Fibrosis Across Medical Contexts

14:00 Interstitial lung disease [Bruno Crestani](#), *University of Paris-Diderot*

14:20 Lung transplant [John Belperio](#), *University of California Los Angeles*

14:40 BOS and cGVHD [Bruce Blazar](#), *University of Minnesota*

15:00 Discussion

15:10 Coffee Break

15:20 Session 5: Translational approaches to studying lung GVHD

15:20 Cell-free DNA in lung transplant [Sean Agbor-Enoh](#), *NIH/National Heart, Lung, Blood Institute*

15:40 Murine models of OB and transplant pulmonary fibrosis [Joe Hsu](#), *Stanford University*

16:00 BOS lung organoids [Carla Kim](#), *Harvard University*

16:20 Ex vivo human lung samples BOS vs. CLAD [Patrick Mellors](#), *Dartmouth University*

16:50 Discussion

17:00 Session 6: Plenary Discussion

[Sophie Paczesny](#) and [Joe Hsu](#)

17:30 ADJOURN Day 1

18:30 Networking Reception

GOAL: Derive a consensus revision of the HCT-BOS definition based on up-to-date evidence

Co-Chairs: [Guang-Shing Cheng](#) and [Anne Bergeron](#)

08:00 Introduction. Why an NIH definition for lung GVHD? The Rationale for a Revision

08:00 From BO to BOS: Defining Lung GVHD [Anne Bergeron, University of Geneva](#)

08:05 Historical context of the lung chronic GVHD definition and response criteria [Steve Pavletic, NIH](#)

08:15 Considerations of practice heterogeneity on the landscape of cGVHD and lung disease [Daniel Wolff, University of Regensburg](#)

08:25 The diagnostic framework and introduction of working proposal [Guang-Shing Cheng, Fred Hutch Cancer Center](#)

08:30 Session 1: Diagnostic Elements: Lung Physiology Chair: [Guang-Shing Cheng](#)

08:30 Basics of PFTs: spirometry, lung volumes, DLCO, and current interpretative strategies [Jane Turner, McMaster University](#)

08:45 Patterns of airflow obstruction, small airways disease, and 'reversibility' relevant to clinical BOS [Gerald Weinhouse, Dana Farber Cancer Institute/Harvard University](#)

09:00 Alternatives to conventional PFTs: handheld spirometry, oscillometry, and MBW [Paul Robinson, University of Queensland, Australia](#)

09:15 Gaps, controversies, and recommendations [Guang-Shing Cheng, Fred Hutch Cancer Center](#)

09:30 Session 2: Diagnostic Elements: Chest Imaging Chair: [Husham Sharifi](#)

09:30 Chest imaging correlates of airflow obstruction [Okka Hamer, University of Regensburg](#)

09:45 Quantitative CT, MRI, and novel approaches to imaging for lung GVHD [Greg Yanik, University of Michigan](#)

10:00 Gaps, controversies, and recommendations [Husham Sharifi, Stanford University](#)

10:15 Coffee Break

10:30 Session 3: Diagnostic Elements: Necessary Conditions and Exclusions Chair: [Ajay Sheshadri](#)

10:30 Pro/Con Debate: Do we need bronchoscopic or surgical lung biopsies? [Aljcia Sadowska-Klasa, Medical University of Gdansk](#) and [Clare Sander, Cambridge University Hospital](#)

10:50 Should absence of infection be a requirement for a diagnosis of lung GVHD? [David Epstein, Stanford University](#)

11:05 Requirements for the cGVHD clinical context and the need for histology [Catherine Lee, Fred Hutch Cancer Center](#)

11:20 Gaps, controversies, and recommendations [Ajay Sheshadri, MD Anderson Cancer Center](#)

11:35 DISCUSSION of Revision Part 1

[Guang-Shing Cheng, Husham Sharifi, Ajay Sheshadri](#)

12:00 LUNCH

13:00 Session 4: Considerations for Special Populations and Scenarios Chair: [Kirsten Williams](#)

13:00 Consideration of preexisting lung disease and the impact of aging on lung function [Hemang Yadav, Mayo Clinic](#)

13:15 The impact of growth on lung function [Shiv Shanthikumar, University of Melbourne](#)

13:30 Specific pediatric considerations for lung function testing, chest imaging, and invasive diagnostic testing [Stella Davies, Cincinnati Children's Hospital](#)

13:45 Recommendations for minimum diagnostic criteria if no diagnostic testing can be obtained [Kirsten Williams, Emory University](#)

14:00 Discussion

14:15 Session 5: Mixed Phenotypes and Non-BOS Lung Entities Co-Chairs: [Jeff Sturek](#) and [Anne Bergeron](#)

14:15 Mixed physiology and non-parenchymal restriction [Jeff Sturek, University of Virginia](#)

14:30 Organizing pneumonia and Interstitial lung disease entities [Yu Kuang Lai, Stanford University](#)

14:45 Pro/Con: Should CLAD-RAS criteria be applied to HCT Lung GVHD? [Saskia Bos, University of Leuven](#) and [Anne Bergeron](#)

15:00 Recommendations and discussion: Include non-BOS as GVHD, and which entities? [Jeff Sturek, University of Virginia](#)

15:15 Coffee Break

15:30 Session 6: Implementation Panel Chair: [Daniel Wolff](#) with an introduction by patient representative [Guy Livneh](#)

Panelists: [Yves Chalandon, University of Geneva](#); [Danielle Stahlbaum, University of Michigan](#); [Anna DeSalvo, National Marrow Donor Program](#); [Sam Goldfarb, University of Minnesota](#); [Paul Carpenter, Fred Hutchinson Cancer Center](#); [Najla El-Jurdi, NIH/National Cancer Institute](#)

16:30 Session 7: Plenary Discussion--Addressing Areas of Controversy

[Guang-Shing Cheng](#) and [Anne Bergeron](#)

17:15 ADJOURN Day 2

GOAL: Establish an ideal clinical trial design and identify clinical trial readiness gaps for Lung GVHD after HCT

Co-Chairs: [Anne Bergeron](#) and [Guang-Shing Cheng](#)

08:00 Introduction

Why we need BOS-specific clinical trials [Corey Cutler, Dana Farber Cancer Institute/Harvard University](#)

08:10 Session 1: Current Therapeutic Landscape for HCT-BOS

[Chair: Anne Bergeron](#)

08:10 Guidelines versus the reality [Hélène Schoemans, University of Leuven](#)

08:25 FDA-approved cGVHD agents for BOS: a pulmonologist's perspective [Anne Bergeron, University of Geneva](#)

08:40 Antifibrotics and the pulmonary drug pipeline [Katrin Hostettler, University of Basel](#)

08:55 Alternative therapies (e.g. ECP) and cGVHD drug pipeline [Daniel Wolff, University of Regensburg](#)

09:10 Q&A / Panel Discussion

09:25 Coffee Break

09:30 Session 2: Clinical Trial Design Elements

[Chair: Guang-Shing Cheng](#)

09:30 Current NIH response criteria, endpoints and limitations [Guang-Shing Cheng, Fred Hutch Cancer Center](#)

09:45 When it's OK to be out of line – modeling continuous data as a non-linear function [Ted Gooley, Fred Hutchinson Cancer Center](#)

10:00 How to Improve the Level of Evidence of Single-Arm Phase 2 Trials. [Sylvie Chevret, University of Paris/Hopital St. Louis](#)

10:15 Biomarkers for Lung GVHD: how do we get there, and how do we test? [Sophie Paczesny, Medical College of South Carolina](#)

10:30 Innovative trial designs in interstitial lung diseases: adaptive, umbrella, basket [Toby Maher, University of California Los Angeles](#)

10:45 Q&A / Discussion

11:00 Insights from the Facebook BOS group: What patients are willing to do to participate in a clinical trial. [Guy Livneh, Palo Alto, California](#)

11:15 Session 2: Clinical Trial Partnerships Panel Discussion

[Co-Chairs: Daniel Wolff and Steve Pavletic](#)

The logistics of establishing multicenter / international collaborations

[Panelists: Val Bhatt \(Incyte\), Dawn Reichenbach \(Sanofi\), Jason Chien \(Mozart Therapeutics\), Gino Cortopassi \(Buto Corp.\), Madhuri](#)

[Vusirikala \(Therakos\), Guy Livneh \(Patient Advocate\), FDA, EMA TBD](#)

12:00 LUNCH

13:00 Session 4: Clinical Trial Design Brainstorming Session

13:00 Small group breakouts: 1) Overall Trial Design, 2) Trial Inclusion and Endpoints, 3) Agents to Test, 4) Correlative Studies, 5) Recruitment and Retention

13:45 Group reports and discussion

14:30 Session 5: Plenary Discussion: White Board Proposal for the Ideal Clinical Trial

15:30 SUMMARY and ADJOURN Day 3 and Meeting

[Guang-Shing Cheng and Anne Bergeron](#)

Thank you to our Lung GVHD Consensus Project Participants

Nicola Adderly, MD[^] University of Calgary, Canada
 Sean Agbor-Enoh, MD, PhD[#] NIH/NHLBI, USA
 Mark Barash, DO[#] Medical College of Wisconsin, USA
 Alan Barker, MD[#] Oregon Health Sciences University, USA
 Anne Bergeron, MD, PhD[#] University of Geneva, Switzerland
 John Belperio, MD[#] University of California Los Angeles, USA
 Julie Boiko, MD, PhD[#] Fred Hutch Cancer Center, USA
 Louise Bondeelle MD, PhD[#] University of Geneva, Switzerland
 Saskia Bos MD, PhD[#] University of Leuven, Belgium
 Bruce Blazar, MD[#] University of Minnesota, USA
 Paul Carpenter, MBBS[#] Fred Hutchinson Cancer Center, USA
 Edward Castillo, PhD[^] University of Texas at Austin, USA
 Yves Chalandon, MD, PhD[#] University of Geneva, Switzerland
 Guang-Shing Cheng, MD[#] Fred Hutchinson Cancer Center, USA
 Sylvie Chevret, MD, PhD[#] University of Paris, France
 Jason Chien, MD, MS[#] Mozart Therapeutics, Seattle, USA
 Julien Cohen, MD, PhD[^] University of Geneva, Switzerland
 Kenneth Cooke, MD[#] Johns Hopkins University, USA
 Bruno Crestani, MD, PhD[#] University of Paris-Diderot, France
 Corey Cutler, MD, MPH[^] Dana-Farber Cancer Institute/Harvard Univ, USA
 Geoffrey Cuvelier, MD[^] Alberta Children's Hospital Foundation, Canada
 Stella Davies MBBS, PhD[#] Cincinnati Children's Hospital, USA
 Anna DeSalvo, MS, CGC[#] National Marrow Donor Program, USA
 David Epstein, MD[#] Stanford University, USA
 Najla El-Jurdi, MD[#] NIH/NCI, USA
 Craig Galban, PhD[^] University of Michigan, USA
 Ted Gooley, PhD[#] Fred Hutchinson Cancer Center, USA
 Sam Goldfarb, MD[#] University of Minnesota, USA
 Okka Hamer, MD[#] University of Regensburg, Germany
 Jörg Halter, MD[^] University Hospital Basel, Switzerland
 Matthew Hensley, MD[^] University of Pittsburgh Medical Center, USA
 Katrin Hostettler, MD, PhD[#] University of Basel, Switzerland
 Véronique Houdouin, MD[^] Robert-Debré University Hospital, France
 Joe Hsu, MD, MPH[#] Stanford University, USA
 Stephen Juvet, MD, PhD[#] University of Toronto, Canada
 Carla Kim, PhD[#] Harvard Medical School, USA
 Yu Kuang Lai, MD[#] Stanford University, USA


Anita Lawitschka, MD, PhD[^] Medical University Vienna and Children's Cancer Research Institute, Austria
 Catherine Lee, MD, MS[#] Fred Hutchinson Cancer Center, USA
 Guy Livneh[#] Palo Alto, California, USA
 Andreas Mall[#] Germany
 Toby Maher, MD, PhD[#] University of California Los Angeles USA
 Patrick Mellors, MD[#] Dartmouth-Hitchcock Medical Center, USA
 David Michonneau, MD, PhD[#] University of Paris, France
 John Murray, RGN, MSc[^] National Health Services, UK
 Sophie Paczesny, MD, PhD[#] Medical College of South Carolina, USA
 Steven Pavletic, MD, PhD[#] NIH/NCI Emeritus, USA and Croatia
 Jonathan Rayment, MD, MSc[^] University of British Columbia, Canada
 Paul Robinson, MD[#] University of Queensland, Australia
 Matthew Rutter[^] Cambridge University Hospitals, UK
 Hélène Salvator, MD, PhD[^] Hospital Foch, France
 Alija Sadowska-Klasa, MD[#] Medical University of Gdansk, Poland
 Clare Sander, MD[#] Cambridge University Hospital, UK
 Hélène Schoemans, MD, PhD[#] University of Leuven, Belgium
 Kirk Schultz, MD, PhD[^] University of British Columbia, Canada
 Shiv Shanthikumar, MBBS, PhD[#] University of Melbourne, Australia
 Husham Sharifi, MD[#] Stanford University, USA
 Ajay Sheshadri, MD, MSc[#] MD Anderson Cancer Center, USA
 Danielle Stahlbaum, MD[#] University of Michigan, USA
 Jeffrey Sturek, MD, PhD[#] University of Virginia School of Medicine, USA
 Jamie Todd, MD[#] Duke University, USA
 Jane Turner, MD[#] McMaster University, Canada
 Gerald Weinhouse, MD[#] Dana-Farber Cancer Institute/Harvard Univ, USA
 Hemang Yadav, MBBS[#] Mayo Clinic Minnesota, USA
 Greg Yanik, MD[#] University of Michigan, USA
 Matthew Zinter, MD[#] University of California San Francisco, USA

* Chair / Task Force Lead
 # Speaker / Panelist
 ^ Task Force Member

Thank you to our Special Advisors:
 Michael Boeckh, MD PhD Fred Hutch Cancer Center, USA
 Stephanie Lee, MD, MPH Fred Hutch Cancer Center, USA

and special thanks to Liz Curtis and Amélie Rivoira

Campus Biotech
 9 Chemin des Mines, 1202 Genève



SCAN CODE TO REGISTER



CONTACT

Amélie Rivoira
 amelie.rivoira@hug.ch

HUG Hôpitaux
 Universitaires
 Genève



**UNIVERSITÉ
 DE GENÈVE**

FACULTÉ DE MÉDECINE